Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples
Table 3
Evaluation of accuracy and precision of the proposed method in pharmaceutical formulations.
| Amount added (ng/mL) | Intraday | Interday | Found | (%) Recovery | Found | (%) Recovery | (ng/μL) ± SD1 | ± RSD3 | (ng/μL) ± SD1 | ± RSD3 |
| SER | | | | | 10 | | | | | 50 | | | | | 100 | | | | |
| PAR | | | | | 10 | | | | | 50 | | | | | 100 | | | | |
| CIT | | | | | 10 | | | | | 50 | | | | | 100 | | | | |
| VLF | | | | | 10 | | | | | 50 | | | | | 100 | | | | |
| FLX | | | | | 10 | | | | | 50 | | | | | 100 | | | | |
|
|
verage of six replicate determinations and their standard deviation, 2RSD: relative standard deviation.
|